Item 8.01 Other Events

On May 17, 2022, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release (the "Press Release") with Abeona Therapeutics Inc. (Nasdaq: ABEO) ("Abeona") announcing that the parties have entered into an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the terms of the license agreement, the Company will assume responsibility for the ABO-102 program and in return Abeona is eligible to receive tiered royalties of up to 10% on net sales and commercial milestone payments following regulatory approval. A copy of the Press Release is filed as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
Exhibit No. Description
99.1          Press Release, dated May 17, 2022
104         The cover page from the Company's Current Report on Form 8-K dated May
            17, 2022 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses